Click for best price
Postpemic Era Nonalcoholic Steatohepatitis NASH Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
Global Nonalcoholic Steatohepatitis (NASH) Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Nonalcoholic Steatohepatitis (NASH) industry at home and abroad, estimate the overall market scale of the Nonalcoholic Steatohepatitis (NASH) industry and the market share of major countries, Nonalcoholic Steatohepatitis (NASH) industry, and study and judge the downstream market demand of Nonalcoholic Steatohepatitis (NASH) through systematic research, Analyze the competition pattern of Nonalcoholic Steatohepatitis (NASH), so as to help solve the pain points of various stakeholders in Nonalcoholic Steatohepatitis (NASH) industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Nonalcoholic Steatohepatitis (NASH) Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Nonalcoholic Steatohepatitis (NASH) Market?
Tobira Therapeutics
Cadila Healthcare
Conatus Pharmaceuticals
Galmed Pharmaceuticals
Gemphire Therapeutics
Genfit
Gilead Sciences
Intercept Pharmaceuticals
Novartis International
Takeda
Major Type of Nonalcoholic Steatohepatitis (NASH) Covered in XYZResearch report:
Obeticholic acid?OCA?
Selonsertib
Emricasan
GR-MD-02
IMM-124E
Application Segments Covered in XYZResearch Market
Hospital Pharmacy
Online Provider
Retail Pharmacy
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Nonalcoholic Steatohepatitis (NASH) Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
89 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Nonalcoholic Steatohepatitis (NASH) Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Nonalcoholic Steatohepatitis (NASH) Market by Value
2.2.1 Global Nonalcoholic Steatohepatitis (NASH) Revenue by Type
2.2.2 Global Nonalcoholic Steatohepatitis (NASH) Market by Value
2.3 Global Nonalcoholic Steatohepatitis (NASH) Market by Sales
2.3.1 Global Nonalcoholic Steatohepatitis (NASH) Sales by Type
2.3.2 Global Nonalcoholic Steatohepatitis (NASH) Market by Sales
3. The Major Driver of Nonalcoholic Steatohepatitis (NASH) Industry
3.1 Historical & Forecast Global Nonalcoholic Steatohepatitis (NASH) Sales and Revenue (2018-2028)
3.2 Largest Application for Nonalcoholic Steatohepatitis (NASH) (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Nonalcoholic Steatohepatitis (NASH) Market
4.1 Regional Market Size in Terms of Sales (2022 & 2028)
4.2 Regional Market Share in Terms of Revenue (2022 & 2028)
4.3 Concentration Ratio (CR5& CR10) of Nonalcoholic Steatohepatitis (NASH) Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Nonalcoholic Steatohepatitis (NASH) Sales (2018-2028)
5.1 Current and Estimated Sales Breakdown by Type (2018-2028)
5.2 Current and Estimated Sales Breakdown by Application (2018-2028)
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Nonalcoholic Steatohepatitis (NASH) Sales (2018-2028)
6.1 Current and Estimated Sales Breakdown by Type (2018-2028)
6.2 Current and Estimated Sales Breakdown by Application (2018-2028)
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Nonalcoholic Steatohepatitis (NASH) Sales (2018-2028)
7.1 Current and Estimated Sales Breakdown by Type (2018-2028)
7.2 Current and Estimated Sales Breakdown by Application (2018-2028)
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Nonalcoholic Steatohepatitis (NASH) Sales (2018-2028)
8.1 Current and Estimated Sales Breakdown by Type (2018-2028)
8.2 Current and Estimated Sales Breakdown by Application (2018-2028)
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Nonalcoholic Steatohepatitis (NASH) Sales (2018-2028)
9.1 Current and Estimated Sales Breakdown by Type (2018-2028)
9.2 Current and Estimated Sales Breakdown by Application (2018-2028)
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Nonalcoholic Steatohepatitis (NASH) Sales (2018-2028)
10.1 Current and Estimated Sales Breakdown by Type (2018-2028)
10.2 Current and Estimated Sales Breakdown by Application (2018-2028)
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Sales (2018-2028)
11.1 Current and Estimated Sales Breakdown by Type (2018-2028)
11.2 Current and Estimated Sales Breakdown by Application (2018-2028)
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. South America Nonalcoholic Steatohepatitis (NASH) Sales (2018-2028)
12.1 Current and Estimated Sales Breakdown by Type (2018-2028)
12.2 Current and Estimated Sales Breakdown by Application (2018-2028)
12.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
12.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
13. Global Nonalcoholic Steatohepatitis (NASH) Average Price Trend
13.1 Market Price for Each Type of Nonalcoholic Steatohepatitis (NASH) in US (2018-2022)
13.2 Market Price for Each Type of Nonalcoholic Steatohepatitis (NASH) in Europe (2018-2022)
13.3 Market Price for Each Type of Nonalcoholic Steatohepatitis (NASH) in China (2018-2022)
13.4 Market Price for Each Type of Nonalcoholic Steatohepatitis (NASH) in Japan (2018-2022)
13.5 Market Price for Each Type of Nonalcoholic Steatohepatitis (NASH) in India (2018-2022)
13.6 Market Price for Each Type of Nonalcoholic Steatohepatitis (NASH) in Korea (2018-2022)
13.7 Market Price for Each Type of Nonalcoholic Steatohepatitis (NASH) in Southeast Asia (2018-2022)
13.8 Market Price for Each Type of Nonalcoholic Steatohepatitis (NASH) in South America (2018-2022)
14. Industrial Chain (Impact of COVID-19)
14.1 Nonalcoholic Steatohepatitis (NASH) Industrial Chain Analysis
14.2 Downstream
14.3 Impact of COVID-19
14.4 Post-pandemic Era
14.5 Technology Trends of Nonalcoholic Steatohepatitis (NASH)
15. Nonalcoholic Steatohepatitis (NASH) Competitive Landscape
15.1 Tobira Therapeutics
15.1.1 Tobira Therapeutics Company Profiles
15.1.2 Tobira Therapeutics Product Introduction
15.1.3 Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Sales, Revenue (2018-2022)
15.1.4 Strategic initiatives
15.2 Cadila Healthcare
15.2.1 Cadila Healthcare Company Profiles
15.2.2 Cadila Healthcare Product Introduction
15.2.3 Cadila Healthcare Nonalcoholic Steatohepatitis (NASH) Sales, Revenue (2018-2022)
15.2.4 Strategic initiatives
15.3 Conatus Pharmaceuticals
15.3.1 Conatus Pharmaceuticals Company Profiles
15.3.2 Conatus Pharmaceuticals Product Introduction
15.3.3 Conatus Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales, Revenue (2018-2022)
15.3.4 Strategic initiatives
15.4 Galmed Pharmaceuticals
15.4.1 Galmed Pharmaceuticals Company Profiles
15.4.2 Galmed Pharmaceuticals Product Introduction
15.4.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales, Revenue (2018-2022)
15.4.4 Strategic initiatives
15.5 Gemphire Therapeutics
15.5.1 Gemphire Therapeutics Company Profiles
15.5.2 Gemphire Therapeutics Product Introduction
15.5.3 Gemphire Therapeutics Nonalcoholic Steatohepatitis (NASH) Sales, Revenue (2018-2022)
15.5.4 Strategic initiatives
15.6 Genfit
15.6.1 Genfit Company Profiles
15.6.2 Genfit Product Introduction
15.6.3 Genfit Nonalcoholic Steatohepatitis (NASH) Sales, Revenue (2018-2022)
15.6.4 Strategic initiatives
15.7 Gilead Sciences
15.7.1 Gilead Sciences Company Profiles
15.7.2 Gilead Sciences Product Introduction
15.7.3 Gilead Sciences Nonalcoholic Steatohepatitis (NASH) Sales, Revenue (2018-2022)
15.7.4 Strategic initiatives
15.8 Intercept Pharmaceuticals
15.8.1 Intercept Pharmaceuticals Company Profiles
15.8.2 Intercept Pharmaceuticals Product Introduction
15.8.3 Intercept Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales, Revenue (2018-2022)
15.8.4 Strategic initiatives
15.9 Novartis International
15.9.1 Novartis International Company Profiles
15.9.2 Novartis International Product Introduction
15.9.3 Novartis International Nonalcoholic Steatohepatitis (NASH) Sales, Revenue (2018-2022)
15.9.4 Strategic initiatives
15.10 Takeda
15.10.1 Takeda Company Profiles
15.10.2 Takeda Product Introduction
15.10.3 Takeda Nonalcoholic Steatohepatitis (NASH) Sales, Revenue (2018-2022)
15.10.4 Strategic initiatives
16. Conclusion
17. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Sales by Application of Nonalcoholic Steatohepatitis (NASH) Industry (Volume)
Figure 2. Nonalcoholic Steatohepatitis (NASH) Sales by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2028)
Figure 4. The Top 10 and 5 Players Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue in 2022
Figure 5. US Nonalcoholic Steatohepatitis (NASH) Sales (2018-2028)
Figure 6. Sales Breakdown by Type (%)
Figure 7. Sales Breakdown by Type (%)
Figure 8. Sales Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Nonalcoholic Steatohepatitis (NASH) Sales (2018-2028)
Figure 12. Sales Breakdown by Type (%)
Figure 13. Sales Breakdown by Type (%)
Figure 14. Sales Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Nonalcoholic Steatohepatitis (NASH) Sales (2018-2028)
Figure 18. Sales Breakdown by Type (%)
Figure 19. Sales Breakdown by Type (%)
Figure 20. Sales Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Nonalcoholic Steatohepatitis (NASH) Sales (2018-2028)
Figure 25. Sales Breakdown by Type (%)
Figure 26. Sales Breakdown by Type (%)
Figure 27. Sales Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Nonalcoholic Steatohepatitis (NASH) Sales (2018-2028)
Figure 31. Sales Breakdown by Type (%)
Figure 32. Sales Breakdown by Type (%)
Figure 33. Sales Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Nonalcoholic Steatohepatitis (NASH) Sales (2018-2028)
Figure 37. Sales Breakdown by Type (%)
Figure 38. Sales Breakdown by Type (%)
Figure 39. Sales Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Sales (2018-2028)
Figure 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Figure 44. Sales Breakdown by Type (%)
Figure 45. Sales Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Nonalcoholic Steatohepatitis (NASH) Revenue, by Type (Million USD) (2018-2028)
Table 4. Nonalcoholic Steatohepatitis (NASH) Sales, by Type (K Unit) (2018-2028)
Table 5. Nonalcoholic Steatohepatitis (NASH) Sales (K Unit) by Application (2018-2028)
Table 6. Nonalcoholic Steatohepatitis (NASH) Sales (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Sales (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2028)
Table 10. Ranking of Global Top Nonalcoholic Steatohepatitis (NASH) Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Nonalcoholic Steatohepatitis (NASH) Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 13. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 14. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 15. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Nonalcoholic Steatohepatitis (NASH) Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 19. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 20. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 21. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Nonalcoholic Steatohepatitis (NASH) Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 25. Table Current and Estimated Sales Breakdown by Type
Table 26. Current and Estimated Sales Breakdown by Type
Table 27. Current and Estimated Sales Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Nonalcoholic Steatohepatitis (NASH) Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 30. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 31. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 32. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Nonalcoholic Steatohepatitis (NASH) Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 36. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 37. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 38. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Nonalcoholic Steatohepatitis (NASH) Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 42. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 44. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 48. Table Current and Estimated Sales Breakdown by Type (2018-2028)
Table 49. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Nonalcoholic Steatohepatitis (NASH) in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Nonalcoholic Steatohepatitis (NASH) in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Nonalcoholic Steatohepatitis (NASH) in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Nonalcoholic Steatohepatitis (NASH) in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Nonalcoholic Steatohepatitis (NASH) in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Nonalcoholic Steatohepatitis (NASH) in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Nonalcoholic Steatohepatitis (NASH) in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Tobira Therapeutics Profiles
Table 61. Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Introduction
Table 62. Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Tobira Therapeutics Strategic initiatives
Table 64. Cadila Healthcare Profiles
Table 65. Cadila Healthcare Nonalcoholic Steatohepatitis (NASH) Product Introduction
Table 66. Cadila Healthcare Nonalcoholic Steatohepatitis (NASH) Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. Cadila Healthcare Strategic initiatives
Table 68. Conatus Pharmaceuticals Profiles
Table 69. Conatus Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Introduction
Table 70. Conatus Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Conatus Pharmaceuticals Strategic initiatives
Table 72. Galmed Pharmaceuticals Profiles
Table 73. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Introduction
Table 74. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Galmed Pharmaceuticals Strategic initiatives
Table 76. Gemphire Therapeutics Profiles
Table 77. Gemphire Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Introduction
Table 78. Gemphire Therapeutics Nonalcoholic Steatohepatitis (NASH) Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Gemphire Therapeutics Strategic initiatives
Table 80. Genfit Profiles
Table 81. Genfit Nonalcoholic Steatohepatitis (NASH) Product Introduction
Table 82. Genfit Nonalcoholic Steatohepatitis (NASH) Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Genfit Strategic initiatives
Table 84. Gilead Sciences Profiles
Table 85. Gilead Sciences Nonalcoholic Steatohepatitis (NASH) Product Introduction
Table 86. Gilead Sciences Nonalcoholic Steatohepatitis (NASH) Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Gilead Sciences Strategic initiatives
Table 88. Intercept Pharmaceuticals Profiles
Table 89. Intercept Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Introduction
Table 90. Intercept Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. Intercept Pharmaceuticals Strategic initiatives
Table 92. Novartis International Profiles
Table 93. Novartis International Nonalcoholic Steatohepatitis (NASH) Product Introduction
Table 94. Novartis International Nonalcoholic Steatohepatitis (NASH) Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. Novartis International Strategic initiatives
Table 97. Takeda Profiles
Table 98. Takeda Nonalcoholic Steatohepatitis (NASH) Product Introduction
Table 99. Takeda Nonalcoholic Steatohepatitis (NASH) Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. Takeda Strategic initiatives
